The emergence of off-brand imatinib represents a notable opportunity for patients battling chronic myeloid leukemia and other diseases. Original brand-name imatinib, commonly known as Gleevec, carries a high price cost, frequently making it accessibility for some individuals. Off-brand versions, gen